CHMP Recommends Saphnelo Subcutaneous Use for Lupus in EU
CHMP Recommends Saphnelo Subcutaneous Administration for SLE in the EU, Offering Convenient Self-Administration Option AstraZeneca has announced that its fully human monoclonal antibody Saphnelo (anifrolumab) has received a positive opinion…
CatalYm Shows Promising Phase 2 Results for Visugromab + PD-1 Inhibitor in Neoadjuvant Bladder Cancer at ESMO
CatalYm Unveils Promising Phase 2 GDFATHER-NEO Data: Visugromab Enhances Anti-Tumor Activity with PD-1 Inhibition in Neoadjuvant Muscle-Invasive Bladder Cancer CatalYm, a pioneering biotechnology company recognized globally for its focus on…
Tezspire Wins U.S. Approval for Nasal Polyps
Tezspire Secures U.S. FDA Approval for Chronic Rhinosinusitis with Nasal Polyps, Expanding Its Reach Beyond Severe Asthma AstraZeneca and Amgen have announced that their jointly developed biologic, Tezspire (tezepelumab), has…
Agenus Shows 39% Two-Year Survival with BOT/BAL in Refractory Solid Tumors at ESMO 2025
Agenus Reports Durable Two-Year Survival with BOT/BAL Combination Across Refractory Solid Tumors at ESMO 2025 Agenus Inc. (Nasdaq: AGEN), a biotechnology company recognized for its pioneering work in immuno-oncology, unveiled…
Roche Reveals 2 Phase III Trial Results for Vamikibart in Uveitic Macular Edema
Roche Unveils Promising Phase III Data for Vamikibart in Uveitic Macular Edema (UME), Highlighting Potential as First-in-Class Non-Steroidal Treatment Option Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced pivotal Phase…
Roquette Launches New Pharma Innovation Center in Latin America
Roquette Opens State-of-the-Art Pharmaceutical Innovation Center in São Paulo to Drive Latin American Healthcare Solutions Roquette, a global leader in plant-based ingredients and pharmaceutical excipients serving the health, nutrition, and…
EMD Serono Strikes Landmark Deal with U.S. to Broaden IVF Therapy Access
EMD Serono Partners with U.S. Government to Expand Access to IVF Therapies for Millions of Americans EMD Serono, the healthcare division of Merck KGaA, Darmstadt, Germany, operating in the United…
ME Therapeutics Licenses CD22 Nanobody to Advance In Vivo CAR Therapy Program
The agreement strengthens ME Therapeutics’ next-generation in vivo CAR cell therapy platform, expanding its pipeline targeting B-cell malignancies through innovative nanobody-based technologies. ME Therapeutics Holdings Inc. (“ME Therapeutics” or the…
FDA Grants Revolution Medicines Priority Voucher for Daraxonrasib (RMC-6236)
Revolution Medicines Receives FDA Priority Voucher for Daraxonrasib (RMC-6236) Under Commissioner’s National Priority Voucher Pilot Program Revolution Medicines Receives FDA Priority Voucher for Daraxonrasib (RMC-6236) Medicines, Inc. (Nasdaq: RVMD), a…
Traditional Medicine in Focus at World Health Summit 2025
raditional Medicine Gains Prominence at World Health Summit 2025 For the first time in its history, the World Health Summit in 2025 highlighted traditional medicine as a core topic, with…
Grifols Opens New U.S. Diagnostic Facility in San Diego
Grifols Strengthens U.S. Diagnostic Manufacturing with New San Diego Facility Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global healthcare company specializing in plasma-derived medicines and innovative diagnostic solutions,…
Taiho Pharma Licenses PI3Kα Inhibitor Risovalisib to Haihe Biopharma
Taiho Pharma and Haihe Biopharma Form Exclusive Japanese Partnership for PI3Kα Inhibitor Risovalisib Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Haihe Biopharma Co., Ltd. (“Haihe”) today announced the signing of an…